ON DEMAND WEBINAR
Duration: 1 hour

Generative artificial intelligence (AI) dominates the headlines today, with strong predictions both positive and negative. Most of these discussions are hypothetical, but in life sciences, AI’s potential to revolutionize one critically important task is abundantly clear: its’ potential to significantly accelerate the regulatory approval process. In this webinar our team of experts explain how AI is already changing the game in the regulatory approval process, including:

• The connection between existing manual approaches to regulatory approvals and the typical 10+ year drug development timeline
• Specific use cases and scenarios where AI can (and cannot) be integrated into regulatory proceedings to improve efficiency
• The challenges facing regulatory affairs leaders and the value of utilizing AI in the regulatory process

SPEAKERS

Andrew Robertson, PhD, JD
Vice President, Global Regulatory Policy and Innovation
Takeda

Lyn Hopkinson
Regulatory Affairs and Quality Executive
CoRA Consulting LLC

Lisa MacNeir
Executive Director of Global Labeling and Regulatory Operations
Stemline